{"denoms":[{"counts":[{"groupId":"BG000","value":"432"},{"groupId":"BG001","value":"429"},{"groupId":"BG002","value":"861"}],"units":"Participants"}],"groups":[{"description":"Participants received pembrolizumab 200 mg intravenously every 3 weeks PLUS axitinib 5 mg orally twice daily.","id":"BG000","title":"Pembrolizumab + Axitinib"},{"description":"Participants received sunitinib 50 mg orally once daily for 4 weeks and then were off treatment for 2 weeks.","id":"BG001","title":"Sunitinib"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.0","value":"61.2"},{"groupId":"BG001","spread":"10.2","value":"60.8"},{"groupId":"BG002","spread":"10.1","value":"61.0"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"124"},{"groupId":"BG001","value":"109"},{"groupId":"BG002","value":"233"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"308"},{"groupId":"BG001","value":"320"},{"groupId":"BG002","value":"628"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"37"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"377"},{"groupId":"BG001","value":"387"},{"groupId":"BG002","value":"764"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"60"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"71"},{"groupId":"BG002","value":"137"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"18"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"343"},{"groupId":"BG001","value":"341"},{"groupId":"BG002","value":"684"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"22"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"138"},{"groupId":"BG001","value":"131"},{"groupId":"BG002","value":"269"}]}],"title":"Favorable"},{"categories":[{"measurements":[{"groupId":"BG000","value":"238"},{"groupId":"BG001","value":"246"},{"groupId":"BG002","value":"484"}]}],"title":"Intermediate"},{"categories":[{"measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"108"}]}],"title":"Poor"}],"description":"Participants were stratified by IMDC risk group using the following criteria: baseline Karnofsky Performance Status \\<80%; interval between initial diagnosis of renal cell carcinoma to start of first-line systemic treatment for advanced disease \\<1year; baseline hemoglobin \\<lower limit of normal (LLN); baseline platelet count \\>upper limit of normal (ULN); baseline corrected calcium1 \\>ULN; and baseline neutrophil \\>ULN. The category was determined by totaling the risk factors per participant and scored as favorable (no factors); intermediate (1 or 2 factors); and poor (≥3 factors).","paramType":"COUNT_OF_PARTICIPANTS","title":"International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Risk Group","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"104"},{"groupId":"BG001","value":"103"},{"groupId":"BG002","value":"207"}]}],"title":"North America"},{"categories":[{"measurements":[{"groupId":"BG000","value":"106"},{"groupId":"BG001","value":"104"},{"groupId":"BG002","value":"210"}]}],"title":"Western Europe"},{"categories":[{"measurements":[{"groupId":"BG000","value":"222"},{"groupId":"BG001","value":"222"},{"groupId":"BG002","value":"444"}]}],"title":"Rest of World"}],"description":"Participants were stratified by geographic region using the following categories: North America; Western Europe; and Rest of the World.","paramType":"COUNT_OF_PARTICIPANTS","title":"Geographic Region","unitOfMeasure":"Participants"}],"populationDescription":"All randomized participants"}